AstraZeneca PLC (LON:AZN) Receives £101.62 Average PT from Brokerages

AstraZeneca PLC (LON:AZN) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is £101.62 ($135.93).

AZN has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £110 ($147.14) price target on shares of AstraZeneca in a report on Tuesday, September 3rd. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a report on Thursday, July 25th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a report on Monday, September 16th. Berenberg Bank reissued a “buy” rating and set a £150 ($200.64) target price on shares of AstraZeneca in a report on Monday, September 2nd. Finally, Jefferies Financial Group increased their target price on AstraZeneca from GBX 71 ($0.95) to GBX 74 ($0.99) and gave the company a “hold” rating in a report on Tuesday, July 2nd.

AstraZeneca Stock Performance

LON AZN opened at £117.92 ($157.73) on Friday. The stock has a market capitalization of £182.78 billion, a price-to-earnings ratio of 3,884.42, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a twelve month low of GBX 9,461 ($126.55) and a twelve month high of £133.88 ($179.08). The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. The stock has a 50-day moving average of £124.82 and a 200 day moving average of £120.31.

AstraZeneca Cuts Dividend

The business also recently declared a dividend, which was paid on Monday, September 9th. Stockholders of record on Thursday, August 8th were given a GBX 77.60 ($1.04) dividend. The ex-dividend date of this dividend was Thursday, August 8th. This represents a dividend yield of 0.64%. AstraZeneca’s dividend payout ratio (DPR) is presently 7,597.40%.

Insider Activity

In related news, insider Michel Demare purchased 2,000 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was acquired at an average cost of GBX 118 ($1.58) per share, for a total transaction of £2,360 ($3,156.77). Company insiders own 0.04% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.